Outcomes associated with matching patients’ treatment preferences to physicians’ recommendations: study methodology

Nasir Umar1*, David Litaker1,2, Marthe-Lisa Schaarschmidt3, Wiebke K Peitsch3, Astrid Schmieder3 and Darcey D Terris1,4

Abstract

Background: Patients often express strong preferences for the forms of treatment available for their disease. Incorporating these preferences into the process of treatment decision-making might improve patients’ adherence to treatment, contributing to better outcomes. We describe the methodology used in a study aiming to assess treatment outcomes when patients’ preferences for treatment are closely matched to recommended treatments.

Method: Participants included patients with moderate and severe psoriasis attending outpatient dermatology clinics at the University Medical Centre Mannheim, University of Heidelberg, Germany. A self-administered online survey used conjoint analysis to measure participants’ preferences for psoriasis treatment options at the initial study visit. Physicians’ treatment recommendations were abstracted from each participant’s medical records. The Preference Matching Index (PMI), a measure of concordance between the participant’s preferences for treatment and the physician’s recommended treatment, was determined for each participant at t1 (initial study visit). A clinical outcome measure, the Psoriasis Area and Severity Index, and two participant-derived outcomes assessing treatment satisfaction and health-related quality of life were employed at t1, t2 (twelve weeks post-t1) and t3 (twelve weeks post-t2). Change in outcomes was assessed using repeated measures analysis of variance. The association between participants’ PMI scores at t1 and outcomes at t2 and t3 was evaluated using multivariate regression analysis.

Discussion: We describe methods for capturing concordance between patients’ treatment preferences and recommended treatment and for assessing its association with specific treatment outcomes. The methods are intended to promote the incorporation of patients’ preferences in treatment decision-making, enhance treatment satisfaction, and improve treatment effectiveness through greater adherence.

Keywords: Patients’ preferences, Patients’ satisfaction, Psoriasis, Psoriasis treatment

Background

Patient-centered care has been defined as being “respectful of and responsive to individual patient preferences, needs and values and ensuring that patient values guide all clinical decisions” [1,2]. Patient-centered care fulfills the obligation of healthcare providers to place the interest of patients first and is associated with improved patient satisfaction, quality of life and better treatment adherence [1,3]. Although current debate exists around the definition of patient-centered care, matching preferences for care with the treatment provided is thought to be one of its key attributes [2,4].

Evidence supports the potential value of matching patients’ preferences to treatment recommendations [4,5]. For example, positive treatment outcomes such as increased satisfaction with treatment and health-related quality of life have been demonstrated when patient preferences for treatment attributes were incorporated into treatment decision-making [5,6]. Matching patients’ preferences for involvement in treatment decision-making to their actual level of involvement has also been associated...
with greater satisfaction with care processes and reduced levels of anxiety once treatment begins [5]. Insights from these studies are somewhat limited, however, by the methods used to elicit preferences. A simple binary approach (i.e. stating a preference for treatment A over treatment B), for example, fails to conform to traditional health economic practices in which measurement of the strength of patients’ preferences for a specific treatment is thought to have greater meaning, and thus greater utility in decision-making. Moreover, the binary approach described fails to reflect the trade-offs made with respect to differing treatment attributes that may drive ultimate treatment choice. In addition, a large number of studies comparing patients’ versus physician treatment preferences use hypothetical scenarios, which provide few insights into the real-world choices that patients actually encounter [7].

Patients’ preferences for treatment have been shown to affect patients’ treatment satisfaction [6,8]. Improvement in treatment satisfaction has been associated with patients’ treatment adherence; patients’ treatment adherence is considered necessary for achieving optimal treatment outcomes [8-11]. Thus, the conceptual model informing this work suggest that the incorporation of patients’ treatment preferences in treatment decision making may influence patients’ clinical (i.e. disease severity) and Health Related Quality of life (HRQoL) outcomes through greater satisfaction and adherence with physician treatment recommendations. Using a prospective cohort study design, our methods aimed to test the hypothesis that a closer match between physicians’ treatment recommendations and patients’ treatment preferences may lead to reduction in disease severity, less impairment in HRQoL, and improvement in treatment satisfaction.

Tools that assess the strength of patients’ preferences for treatment recommendations and potential trade-offs among treatment attributes are needed. The availability of such tools may enable more accurate assessment of the effects of preference matching on treatment outcomes. In this report, we describe the methods we used in a study that assessed the association of preference matching with objective clinical and participant-derived outcomes.

Methods
Setting
This study is being carried out in a bi-weekly outpatient psoriasis clinic in the Department of Dermatology, University Medical Centre Mannheim, University of Heidelberg, a regional ‘Competence Centre for Psoriasis.’ The psoriasis clinic is a primary, secondary and tertiary care referral centre, to which patients are referred by family physician, general medical practitioners, general internist, dermatologists and other community hospitals from the Metropolitan Region Rheine-Necker. The clinic therefore attends to population of patients with wide spectrum of the disease. Approximately 250 to 300 patients with moderate to severe psoriasis attend these clinics annually, making it a site at which it would be feasible to recruit participants with a range of clinical characteristics and disease severity.

Participants
Study participants were patients attending the outpatient psoriasis clinic in the Department of Dermatology, University Medical Centre Mannheim. University of Heidelberg.

Inclusion criteria: participants were included if they were 18 years of age or older and were new or established patients in the Department of Dermatology. Each had physician-diagnosed moderate or severe psoriasis according to the criteria of the Committee for Medicinal Products for Human Use [12], i.e., a Psoriasis Area and Severity Index (PASI) ≥ 10, involvement of the head, the palmar or plantar surfaces, or psoriatic arthritis with any skin involvement and patients on systemic anti-psoriatic therapy. These criteria were purposefully selected to ensure that participants in the sample would require one or more treatments from a broad range of available options. Exclusion criteria: Participants were excluded if they were not able to complete the online survey independently or if they were unable to read and understand German (the language in which the survey and subsequent interviews were conducted).

Recruitment
To recruit a consecutive sample, each patient with moderate or severe psoriasis attending dermatology outpatient clinics was approached. Two members of the research team were responsible for all aspects of recruitment, including the distribution of informational leaflets about the study, identification of potentially eligible participants, assessment of eligibility (i.e., applying inclusion/exclusion criteria) and obtaining informed consent. Once identified, eligible participants were approached before their appointment with the physician and invited to participate in the study. Informed consent was then obtained, a unique four-digit study identification number was assigned and the two study follow-up visits were scheduled (t2 (twelve weeks post-t1) and t3 (twelve weeks post-t2)). After completing an online survey (described below), participants proceeded to their medical appointment. Steps in recruitment and data collection are summarized in Table 1.

Data elements
The primary independent variable was the Preferences Matching Index (PMI), a measure of concordance developed in three steps: Step 1 involved the elicitation of participants’ preferences for available treatment options in terms of their “attributes” (i.e., processes or potential...
Table 1 Steps involved in participants’ recruitment and data collection

| Recruitment/ Data collection steps | Activities |
|-----------------------------------|------------|
| 1. Participant recruitment        | Participants were approached at the outpatient clinic while waiting for their doctor's appointment. The setting was considered convenient for recruitment as it provided access to relatively large numbers of potential participants who fit the study's inclusion criteria. Further, since patients have to wait for their doctor's appointment at the outpatient clinic, asking participants to answer the survey during this waiting period was not viewed as imposing an undue burden on their time. |
| 2. Informed consent               | Patients who agreed to participate completed and returned a signed informed consent form. |
| 3. Allocation of study identification number/initial screening | Participants who returned the signed consent forms and were considered eligible were assigned study identification numbers for anonymity. Appointment dates were also set for subsequent follow-up visits. |
| 4. Administration of the survey   | Participants were guided to the room and computer where they completed the survey. |
| 5. Doctor’s appointment           | After completing the survey, participants were directed to their respective doctor’s appointment. |
| 6. Data abstraction and forwarding | Participants’ PASI scores and doctor’s treatment recommendation were abstracted from the medical records and faxed to the study coordination center at the Mannheim Institute of Public Health (MIPH) for entry into a database. |
| 7. Participant screening          | Inclusion and exclusion criteria were further applied at this stage, using the abstracted data, to screen participants for eligibility. |
| 8. Non-eligible patients          | Participants considered non-eligible were not followed for subsequent study visits and their records were deleted. |
| 9. Eligible patients              | Eligible patients were followed for subsequent study visits and their records were stored according to data protection laws. |
| 10. t1 (initial study visit)      | Initial study visit data was collected. |
| 11. t2 (12 weeks after t1)        | First follow-up visit data was collected. |
| 12. t3 (12 weeks after t2)        | Second follow-up visit data was collected. |
| 13. Study coordination and data storage at MIPH | The survey data forwarded from the study site (dermatology department) was securely stored at the MIPH. |

outcomes of treatment [see Table 2] [13]) and attribute “levels” or “categories” (i.e., the possible forms a treatment might take). In Step 2, physicians’ treatment recommendations were abstracted from participants’ medical records. Step 3 entailed the calculation of the PMI using a process of conjoint analysis to quantify concordance between participants’ treatment preferences and the treatment recommended at the initial study visit at (t1) by the physician. The PMI was determined only at t1 (initial study visit). Each step is described below in detail.

Elicitation of patients’ preferences (Step 1)

‘Patients’ preferences’ here refers to the value patients attach to different treatment attributes when faced with treatment options. A range of potentially appropriate and currently available psoriasis treatments modalities were identified by using the ‘German evidence-based guidelines for the treatment of psoriasis’ [14] and by consultations with clinical experts (AS and WP). Process and outcomes of currently available treatments were decomposed into attributes and attribute levels or categories. This process was guided by review of studies that assessed preferences for psoriasis treatments [5,6,15].

Four attribute levels or categories were specified for each treatment attribute (Table 2) [13]. Although a large number of attribute levels could have been developed, we decided to limit confine the number to four categories to limit respondent burden and avoid information overload. We further refined attribute categories for clarity of content using comments from the participants, following a pilot of the conjoint analysis exercise described below. Treatment attributes and attribute categories were labeled to distinguish elements of the process of treatment from those resulting from the care (outcomes). Examples of process attributes included the ‘delivery method’ (mode of drug administration) or ‘location of treatment’. An example of attribute categories for the process-related treatment attribute ‘location of treatment’ included: ‘treatment at home’, ‘treatment at the local doctor’s office’, ‘treatment at an outpatient clinic’, and ‘treatment at an inpatient clinic’. Examples of outcome attributes included the ‘severity of potential side effects’, ‘possibility of beneficial effect’ and ‘reversibility of side effects’ that may result from a particular psoriasis treatment modality. A full list of attributes and attribute categories is provided in Table 2 [13].

We used ‘choice-based conjoint analysis’ (CBC) to measure participants’ preferences for specific psoriasis treatments. This method best simulates the way people make everyday choices when faced with multiple options [16] and has the additional advantages of being previously validated, easy to use, and efficient in assessing patients’ preferences for health care and their treatment priorities [16]. To conduct our analysis, we used survey design software
(Sawtooth, Inc., Sequim, WA) to present participants with twelve pair-wise comparisons comprised of random combinations (see Table 3) [13] of the profiled attribute categories (twelve random combinations of attribute categories per pair). In a final analytical step, “preference scores” (partworth utilities values) were generated for every participant for each attribute level or category of psoriasis treatment option, with higher scores indicating a

Table 2 Profile of treatment attributes and attribute levels

| Treatment Attribute          | Attribute Levels (categories)                                                                 |
|------------------------------|---------------------------------------------------------------------------------------------|
| Treatment duration*          | Each treatment will take:                                                                  |
|                              | • 5 minutes to complete.                                                                    |
|                              | • 15 to 30 minutes to complete.                                                            |
|                              | • 1 hour to complete.                                                                     |
|                              | • 2 hours to complete.                                                                    |
| Treatment frequency*         | My treatment will occur:                                                                   |
|                              | • Once every three months.                                                                 |
|                              | • Once every two weeks.                                                                    |
|                              | • Two times each week.                                                                    |
|                              | • Twice daily.                                                                             |
| Treatment cost*              | I will have to pay:                                                                       |
|                              | • Nothing to cover the cost of my treatments.                                             |
|                              | • An additional 50 € per month to cover the cost of my treatments.                        |
|                              | • An additional 100 € per month to cover the cost of my treatments.                       |
|                              | • An additional 200 € per month to cover the cost of my treatments.                       |
| Treatment location*          | My treatment will take place:                                                              |
|                              | • At home.                                                                                 |
|                              | • At home with follow-up at my local doctor’s office.                                      |
|                              | • At an outpatient clinic.                                                                 |
|                              | • While I stay in the hospital for three weeks.                                           |
| Treatment delivery method*   | My treatment will occur by:                                                                |
|                              | • Applying medication on my skin.                                                          |
|                              | • Taking Tablets.                                                                          |
|                              | • Having an injection/intravenous infusion.                                                |
|                              | • Light therapy.                                                                          |
| Magnitude of beneficial effect* | I will likely experience:                                                             |
|                              | • Almost a 100% reduction in my psoriasis plaques.                                        |
|                              | • About a 75% reduction in my psoriasis plaques.                                          |
|                              | • About a 50% reduction in my psoriasis plaques.                                          |
|                              | • About a 25% reduction in my psoriasis plaques.                                          |
| Duration of beneficial effect* | The improvement in my psoriasis will last for:                                           |
|                              | • 1 year or more after completing all of my treatments.                                   |
|                              | • 6 to 8 months after completing all of my treatments.                                     |
|                              | • 3 to 5 months after completing all of my treatments.                                     |
|                              | • 2 weeks after completing all of my treatments.                                          |
| Probability of side effects* | There is:                                                                                 |
|                              | • Almost a 100% chance that I will experience side effects from the treatment.            |
|                              | • About a 50% chance that I will experience side effects from the treatment.              |
|                              | • About a 10% chance that I will experience side effects from the treatment.              |
|                              | • Less than 1% chance that I will experience side effects from the treatment.             |
| Probability of beneficial effect* | I have:                                                                    |
|                              | • Almost a 100% chance of experiencing a significant reduction in my psoriasis.          |
|                              | • About an 80% chance of experiencing a significant reduction in my psoriasis.           |
|                              | • About a 60% chance of experiencing a significant reduction in my psoriasis.           |
|                              | • About a 40% chance of experiencing a significant reduction in my psoriasis.           |
| Reversibility of side effects* | If side effects occur, there is:                                                          |
|                              | • Almost 100% chance that I will completely recover once my treatments are stopped.       |
|                              | • About an 80% chance that I will completely recover once my treatments are stopped.       |
|                              | • About a 60% chance that I will completely recover once my treatments are stopped.       |
|                              | • About a 40% chance that I will completely recover once my treatments are stopped.       |
| Side effect severity*        | I may experience:                                                                         |
|                              | • Temporary, minor discomfort on my skin.                                                  |
|                              | • Constant, moderate discomfort on my skin.                                                |
|                              | • Temporary, moderate side effects that can effect more than my skin.                     |
|                              | • Severe side effects that can effect more than my skin.                                   |

Note: (*) = Process attributes and levels; (**) = Outcome attributes and levels
greater preference. It is important to note that even though a subset of potential treatments were randomly selected and presented to the participant, the software algorithm (using an orthogonal design) is programmed to extrapolate preference values for all possible treatments and treatment levels for each study participant.

**Abstraction of physician-recommended treatments (Step 2)**

A member of the research team (MS) trained in the interpretation of data documented in medical records was responsible for abstracting data on the actual treatment modalities recommended by physicians for each participant. Participants’ medical records were retrieved after their clinical visit at t1 and data were abstracted using a standardized data collection form and entered into a database. Accuracy of data entry was confirmed by review at each subsequent study visit of all previously recorded data. In the event of multiple treatment recommendations at t1, all were recorded.

**Determining the level of concordance (Step 3)**

First we identify participants’-preferred treatments and most preferred attribute categories with the highest scores; we also identified participants’ least preferred treatment and least preferred attribute categories with the lowest scores from the conjoint analysis described above. The same process was followed for identifying the scores associated with the physician-recommended treatments, and their associated attributes, for each participant.

To illustrate, if Table 4 represents preference scores from a conjoint analysis for a hypothetical participant presented with three randomly selected treatment attributes, the participant appears to most prefer light therapy treatment (preference score = 44) at an outpatient clinic (preference score = 19) lasting between 15-30 minutes (preference score = 27). If the treatment recommended by the physician for this participant was ‘methotrexate tablets’, the attribute categories ascribed to this treatment would be: “tablets”, “ taken at home” and “5 minutes” for anticipated treatment type, location, and anticipated duration, respectively. These attribute categories correspond to participant-derived preference scores of 10, 17 and 23 (Table 4).

Next, scores for treatment attribute categories most preferred by the participants (attribute categories with the highest preferences score) and attribute categories least preferred by the participants (attribute categories with lowest preference scores) were summed. Further, scores for physician recommended treatment were

---

**Table 3 Example of treatment scenarios presented to the study participants in the conjoint analysis survey**

| Option A                                                                 | Option B                                                                 |
|-------------------------------------------------------------------------|--------------------------------------------------------------------------|
| My treatments will take place at home.                                   | My treatments will take place while I stay in the hospital for three weeks. |
| My treatments will occur twice daily.                                    | My treatment will occur once every three months.                          |
| Each treatment will take one hour to complete.                           | Each treatment will take 15 to 30 minutes to complete.                    |
| I may experience constant, moderate side effects that can affect more than my skin. | I may experience constant, minor discomfort on my skin.                  |
| I have about an 80% chance of experiencing a significant reduction in my psoriasis plaques. | I have almost a 100% chance of experiencing a significant reduction in my psoriasis plaques. |
| The improvement in my psoriasis will last for 3 to 5 months after completing all of my treatments. | The improvement in my psoriasis will last for 3 to 5 months after completing all of my treatments. |

---

**Table 4 Example of preferences scores (partworth utilities) for treatment attributes and attribute levels for a hypothetical respondent**

| Treatment attributes | Attribute categories | Preference score (utilities) |
|----------------------|----------------------|-----------------------------|
| Attribute 1. Treatment delivery method | Category 1. Topical | -74                         |
|                       | Category 2. Tablets  | 10                          |
|                       | Category 3. Injection/infusion | 20                   |
|                       | Category 4. Light therapy | 44                   |
| Attribute 2. Treatment location | Category 1. At home | 17                          |
|                       | Category 2. At local doctor’s office | 2                   |
|                       | Category 3. At outpatient clinic | 19                  |
|                       | Category 4. Hospital stay | -34                      |
| Attribute 3. Treatment duration | Category 1. 5 minutes to complete | 23                   |
|                       | Category 2. 15-30 minutes to complete | 27                  |
|                       | Category 3. 1 hour to complete | -26                      |
|                       | Category 4. 2 hours to complete | -24                      |
assessed T1, T2 (twelve weeks post-T1) and T3 (twelve weeks post-T2). Twelve weeks are known to be sufficient to judge the short-term effectiveness of a psoriasis treatment, but we specifically wanted to look at longer-term outcomes at 24 weeks which may better represent sustainable treatment adherence [18].

We then constructed a scale with two end points: the participants’ most preferred treatment and the participants’ least preferred treatment (Figure 1). To determine the PMI, the range between the preference scores for recommended treatment and the least preferred treatment was divided by the range between the most preferred treatments and the least preferred treatment or b/c (Figure 1). In the example, the PMI is therefore [50-(-134)]/90-(-134)], representing the concordance between the preference scores for the physician treatment recommendations and preference scores for the participants’ preferred treatment. The PMI ranges between 0 (no preference concordance) and 1 (complete preference concordance). To ensure data quality and the accuracy of the PMI computed, we repeated calculations at each stage. In the rare instances in which discrepancies were found, we returned to the original data to confirm and re-enter values.

The dependent variables in our analysis consisted of both objective clinical and participant-derived outcome measures (Table 5). The dependent variables were assessed T1, T2 (twelve weeks post-T1) and T3 (twelve weeks post-T2). Twelve weeks are known to be sufficient to judge the short-term effectiveness of a psoriasis treatment, but we specifically wanted to look at longer-term outcomes at 24 weeks which may better represent sustainable treatment adherence [18]. Our analyses therefore focused on changes observed between T1 and T3, although additional analyses (not described here) were also performed for changes observed between T1 and T2.

The primary dependent variable was the change in PASI score from T1 to T3. The PASI is a psychometrically valid and reliable instrument routinely applied in dermatology to assess psoriasis severity and gauge treatment effects [17]. PASI combines assessment of the severity of psoriasis lesions and the area affected into a score ranging from 0 (no disease) to 72 (maximal disease), with scores ≥ 10 reflecting moderate to severe disease [17].

The secondary dependent variables included change in patients’ satisfaction with treatment from T1 to T3 measured by the Treatment Satisfaction Questionnaire for Medication (TSQM) and change in self-reported health-related quality of life (HRQL) from T1 to T3 measured by the Dermatology Quality of Life Index (DLQI). TSQM is a 14-item, psychometrically validated instrument [18]. The DLQI, a validated questionnaire, is one of the most widely used instruments to assess the health-related quality of life of patients with skin conditions. DLQI scores range from 0 to 30, with higher scores indicating greater impairment in skin disease-specific quality of life [19].

We identified potential confounding characteristics including sex (male, female); age (measured in years); partnership status (i.e., living with a partner, not living with a partner, widowed); employment status (i.e., full-time, part-time, not working); highest educational attainment (i.e., no school, primary school equivalent, secondary school equivalent, post-secondary school training, university, post-university) and net annual household income (measured in Euros) [20,21]. Based on previous work, we measured a number of factors that might moderate participants’ satisfaction and compliance with treatment, including treatment history (i.e., previously prescribed treatments) and disease-related factors (i.e., time since diagnosis and co-morbidities [e.g. depression: yes/no]) [21].

Data sources/data collection
As previously mentioned, data were obtained from two sources: participants’ survey responses and physicians’ notations in their medical records (Table 5). The survey, developed using ‘Sawtooth Survey Software for Online Interviewing’ (Sawtooth, Inc., Sequim, WA), was administered in the dermatology clinic using either a desktop computer or laptop located in a separate room away from the waiting area. A member of the research team was available to demonstrate how the survey instrument functioned. Data collected via the online survey was stored in a secure server and accessed for analysis via the Internet.

Analytic strategy
Design
We utilized a prospective cohort study design to assess the association of the concordance between patients’ preferences to physician-recommended treatments with subsequent treatment outcomes.

Sample size
To detect a moderate-sized change in our primary outcome measure between T1 and T3, we set an effect size (F2) of 0.15 [12], α = 0.05 and β = 0.20. Using these parameters, we estimated that a minimum sample size of 200 was needed. Adjusting for a possible dropout rate of 20%
at both the t2 and t3 follow-up visits, we increased the required sample size to 240 patients. We considered this recruitment goal to be attainable given the annual patient volume at the study site.

Specific aims, tasks and hypotheses
Our methods aimed to address the following:

- To develop the Preference Matching Index (PMI) as a novel metric that assesses the concordance between a physician’s treatment recommendation and a participants’ most preferred treatment.

| Table 5 Variables, measurement instruments and data sources |
|-------------------------------------------------------------|
| **Variable** | **Measurement Instrument** | **Data Source** | **Data Collection Period** |
| Independent Variable | | | |
| PMI | Conjoint analysis survey/Doctors’ recommendations | Participants | t1 |
| PMI | Doctors’ recommendations | Participants’ medical records | t1, t2, t3 |
| Dependent Variable | | | |
| PASI scores | Physician-assessed PASI [17] | Participants’ medical records | t1, t2, t3 |
| TSQM scores | Self-reported TSQM questionnaire [18] | Participants | t1, t2, t3 |
| DLQI scores | Self-reported DLQI questionnaire [19] | Participants | t1, t2, t3 |
| Confounders | | | |
| Demographic factors | Standard German demographic questionnaire | Participants | t1 |
| Treatment factors | Self-reported questionnaire | Participants | t1 |
| Disease-related factors | Self-reported questionnaire | Participants | t1 |

Note: DLQI = Dermatology Quality of Life Index; PASI = Psoriasis Area and Severity Index; TSQM = Treatment Satisfaction Questionnaire for Medication; t1 = initial study visit; t2 = first follow-up study visit twelve weeks after t1; t3 = second follow-up study visit twelve weeks after t2

Umar et al. BMC Health Services Research 2012, 12:1
http://www.biomedcentral.com/1472-6963/12/1
change in measures of satisfaction with treatment between \( t_1 \) and \( t_3 \).

**Hypotheses:** There will be statistically significant negative associations between participants’ PMI and absolute change in change in HRQL between \( t_1 \) and \( t_3 \).

**Statistical analysis**
Baseline data will be used to identify factors associated with participants’ preferences and treatment satisfaction, HRQoL and disease severity in the study sample. Data of participants’ lost to follow-up will examine the characteristics associated with dropout. Change in outcome measures across the three data collection points will be assessed using repeated measure analysis of variance. The relationship between participants’ PMI scores and each of the three study outcomes will be evaluated using separate multivariate linear regressions models: the association of PMI with the objective clinical outcome (model 1) and the association of PMI with patient reported treatment satisfaction (model 2) and HRQL (model 3), controlling for known confounders (e.g. age, education, marital status and income) [22]. In sensitivity analysis, we will stratify our analysis by gender, and by new and established (old) patients; treatment experience (new or old) may affect patients’ treatment preferences [23].

**Ethical and human subjects’ confidentiality**
The ethics committee of the Medical Faculty Mannheim, University of Heidelberg granted approval for the study (ID 2009-329E-MA). The methodology used in this study followed the principles of the Helsinki Declaration. Statistical analyses were performed using either Sawtooth software (Sawtooth, Inc., Sequim, WA) or SPSS statistical package version 19 (Chicago, IL).

**Discussion**
In this paper, we describe the methods used to develop a measure of the concordance between patients’ preferences for treatment and actual treatment recommendations. We also detail the methods used to assess the association of this measure with both objective clinical and patient-derived outcomes.

Substantial effort has been devoted to creating a health care environment in which the needs and preferences of patients are both acknowledged and incorporated into decision-making. Unfortunately, the tools available to support this effort are limited in both quantity and quality. Ideally these tools should be capable of assessing a broad spectrum of available medical interventions (i.e., the processes of care) and realistic outcomes of care. Conjoint analysis best simulates the way people make everyday choices when faced with multiple options and can help identify treatment features that drive patients’ treatment preferences [9]. Further, conjoint analysis has the additional advantages of being validated, easy to use, and increasingly recognized as an efficient way to assess patients’ preferences for health care and their treatment priorities [16]. In addition, in routine clinical practice or research, the preference scores derived from the conjoint exercises can be compared with treatment recommendations from physicians to determine the extent of preference matching and sharing [16].

The methods we describe may be applied to decision-making for the management of other chronic diseases. Although such applications requires an initial investment of time and expertise in revision of the conjoint analysis survey, the introduction of new treatments (attributes and attribute levels) can be subsequently added with relative ease to data previously stored by the program. Our work uses psoriasis as an example of a common chronic disease, yet we fully expect that this methodology may be useful in promoting shared decision-making in the management of other diseases.

Mismatch between physicians’ and patients’ treatment preferences have been reported [24]. Mismatch between physicians’ and patients’ treatment preferences may result in patients receiving treatment they are dissatisfied with, which may affect their adherence to the recommended treatments [24]. Understanding the association of preference matching (captured by the PMI) with treatment outcomes may provide important insight on the potential value of using psoriasis patients’ preferences in shared decision-making.

Based on the preference scores elicited from the conjoint analysis, it is possible for a patient to have equal or near equal preference for two different treatment options [25], if the two treatment options share certain attributes the patient value equally (e.g. a tablet and a cream can both be taken at home and their administration may take less time). This has important implication in treatment decision; it gives room for a more meaningful shared decision-making to happen. Physicians can acknowledge patients preferences, and still have the freedom to trade between different treatment attributes and attribute levels when making treatment recommendations.

Despite the strength of the methods we have described, a number of limitations should be acknowledged. Participants may, for example, report biased preferences when completing the conjoint exercise due to a ‘dominant preference’ for a particular attribute. That is, they may refuse to trade between treatment attribute categories because of strong feelings about the perceived nature of some treatments. Second, we have not measured adherence directly. The conceptual model informing this work suggests, however, that satisfied patients are more likely to adhere to recommended treatments and that this explains, to some extent, the presence of more desirable outcomes. Finally, some have suggested that the process of preference elicitation may influence subsequent reporting of treatment...
satisfaction or disease-specific quality of life. To guard against this, we assessed preferences before consultation and did not share these results with patients at any point during the study.

Conclusion
We describe a novel method for measuring concordance between patients’ most preferred treatments and physicians’ recommended treatments and for assessing the association of concordance with treatment outcomes. Tailoring treatment recommendations to patients’ preferences is an essential part of patient-centered care. Efforts to implement preference-based tailoring in routine clinical care may improve the quality of the interaction between patients and physicians, patients’ adherence with treatment, satisfaction with treatment and clinical outcomes achieved. The methods reported here, although originally tested within the context of psoriasis treatment, have the potential to advance greater patient-centeredness in the management of other chronic diseases.

Abbreviations
PMI: Preference Matching Index; HRQoL: Health Related Quality of Life; PASI: Psoriasis Area and Severity Index; TSQM: Treatment Satisfaction Questionnaire for Medication; DLQI: Dermatology Quality of Life Index.

Acknowledgements
This project is a collaborative work between the Mannheim Institute of Public Health, Social and Preventive Medicine of the Medical Faculty Mannheim, Heidelberg University and the Dermatology Department of the Medical Faculty Mannheim, Heidelberg University. We are indebted to Ursula Goldberger (Mannheim Institute of Public Health (MIPH)) for translating our questionnaires into German; Christine Schwarze-Abele (MIPH), Alexander Maier (MIPH) and Paul Kettانnar (MIPH) for general support; Jasper Sheppe (University of Mannheim) for important inputs; Anette Oberst (Department of Dermatology, University Medical Centre Mannheim) for help with documentation and to the doctors and nursing staff from the Department of Dermatology at the University Medical Centre Mannheim for support with patient recruitment. We thank all patients for participation in the study and for providing written informed consent for publication.

Author details
1Mannheim Institute of Public Health, Social and Preventive Medicine and the Competence Center for Social Medicine and Occupational Health Promotion, Medical Faculty Mannheim, University of Heidelberg, Ludolf-Krehl-Str. 7-11, 68167 Mannheim, Germany. 2Departments of Medicine, Epidemiology and Biostatistics, Case Western Reserve University, Cleveland Ohio, USA. 3Department of Dermatology, University Medical Centre Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68135 Mannheim, Germany. 4Department of Health Policy and Management, College of Public Health, University of Georgia, Athens, Georgia, USA.

Authors’ contributions
Study concept and design: NU, WKP, AS & DDT. Drafting of the manuscript: NU & DDT. Critical revision of the manuscript for important intellectual content: NU, DL, MS, WKP, AS & DDT. Administrative, technical, or material support: NU, MS, WKP, AS & DDT. Study supervision: NU, WKP & DDT. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 28 March 2011 Accepted: 3 January 2012 Published: 3 January 2012

References
1. Epstein RM, Fiscella K, Lesser CS, Stange KC. Why the nation needs a policy push on patient-centered health care. Health Aff (Millwood) 2010, 29(8):1489-1495.
2. Institute-of-Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington (DC): National Academies Press; 2001.
3. Roume CL, Greevy R, Wallston KA, Elasy TA, Kaltenbach L, Kotter K, Dittus RS, Speroff T. Patient centered primary care is associated with patient hypertension medication adherence. J Behav Med 2010.
4. Robinson JP, Callister LC, Berry JA, Dearing KA. Patient-centered care and adherence: definitions and applications to improve outcomes. J Am Acad Nurse Pract 2008, 20(12):600-607.
5. Kiesler DJ, Auerbach SM. Optimal matches of patient preferences for information, decision-making and interpersonal behavior: evidence, models and interventions. Patient Education and Counseling 2006, 61(3):319-341.
6. Leducue L, Tuten Nothenius JL, Bos JD, Spuls PI. Patient preferences and satisfaction with systemic therapies for psoriasis: an area to be explored. Br J Dermatol 2009, 160(6):1340-1343.
7. Sepucha K, Ozanne EM. How to define and measure concordance between patients’ preferences and medical decisions: A systematic review of approaches and recommendations for standardization. Patient Education and Counseling 2010, 78(1):12-23.
8. Ventura Cerda JM, Casado Gomez MA, Escobar Rodriguez J, Ibarra Barrueta O, Ortega Valin L, Morales Gonzalez JM, Coterele Suarez M. Preferences, satisfaction and compliance with antiretroviral treatment: ARPPAS study (II). Farm Hosp 2007, 31(6):340.
9. Waked MS, Manal SI, Khalis SJ, Adham SAT, Ansam FS, Sa’ed HZ, Ransah MJ, Donald EM. Self-reported medication adherence and treatment satisfaction in patients with epilepsy. Epilepsy & Behavior 2011, 21:301-305.
10. Leo R, Jassal K, Bakhair Y. Nonadherence with Psychopharmacologic Treatment among Psychiatric Patients. Primary Psychiatry 2006, 12(6):33-38.
11. Zweben A, Perrinati HM, Weiss RO, Youngblood M, Cox CE, Martinson ME, Gorocochua P, Ciraulo D. Relationship between medication adherence and treatment outcomes: The COMBINE study. Alcoholism-Clinical and Experimental Research 2008, 32(9):1661-1669.
12. Claas C. Therapie der mittelschweren und schweren Psoriasis, In: Schriftenreihe Health Technology Assessment (HTA) in der Bundesrepublik Deutschland Aufl. DMDI Deutsche Agentur für das Deutsches Institut für Medizinische Dokumentation und Information, Köln, 2006.
13. Schaarschmidt ML, Schmieder A, Umar N, Terris D, Goebeler M, Goerdts S, Welteke KP. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Arch Dermatol 2011, 147(11):1285-1294.
14. Nast A, Kopf I, Augustin M, Bandt K, Boehmke WH, Vollmann M, Friedrich M, Huber M, Kahl C, Klaus J et al. German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version), Arch Dermatol Res 2007, 299(3):111-138.
15. Doherty C, Doherty W. Patient’s preferences for involvement in clinical decision-making within secondary care and the factors that influence their preferences. J Nurs Manag 2005, 13(2):119-127.
16. Say RE, Thomson R. The importance of patient preferences in treatment decisions-challenges for doctors. BMJ 2003, 327(7414):542-545.
17. Ithato D, Fadzil MH, Affandi AM, Hussein SH. Area assessment of psoriasis lesion for PASI scoring. Conf Proc IEEE Eng Med Biol Soc 2007, 2007:3464-3469.
18. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004, 2:12.
19. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19(3):210-216.
20. Mrowietz U, Kragballe K, Nast A, Reich K. Strategies for improving the quality of care in psoriasis with the use of treatment goals—a report on an implementation meeting. J Eur Acad Dermatol Venereol 2011, 25(Suppl 3):1-13.
21. Reich K, Mrowietz U. Treatment goals in psoriasis. Journal Der Deutschen Dermatologischen Gesellschaft 2007, 5(7):565-574.
22. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM: Statistics in medicine–reporting of subgroup analyses in clinical trials. *N Engl J Med* 2007, 357(21):2189-2194.

23. Denberg TD, Melhado TV, Steiner JF: Patient treatment preferences in localized prostate carcinoma: The influence of emotion, misconception, and anecdote. *Cancer* 2006, 107(3):620-630.

24. Vogel BA, Helmes AW, Hasenburg A: Concordance between patients’ desired and actual decision-making roles in breast cancer care. *Psychooncology* 2008, 17(2):182-189.

25. Bowles S: Endogenous preferences: The cultural consequences of markets and other economic institutions. *J Econ Lit* 1998, 36(1):75-111.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6963/12/1/prepub

doi:10.1186/1472-6963-12-1

Cite this article as: Umar et al. Outcomes associated with matching patients’ treatment preferences to physicians’ recommendations: study methodology. *BMC Health Services Research* 2012 12:1.